Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fate TherapeuticsFATE +0.20%33 Cash-to-Debt is 2.03 as of Jun. 2026, which is 56% below its 10-year median of 4.62. GuruFocus rates FATE with a GF Score™ of 33/100 and a GF Value™ of $0.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,397 Biotechnology companies, Fate Therapeutics ranks worse than 67.86% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Fate Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 2.03.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Fate Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Fate Therapeutics's Cash-to-Debt or its related term are showing as below:
FATE'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.03 Med: 4.62 Max: 14.21
Current: 2.03
During the past 13 years, Fate Therapeutics's highest Cash to Debt Ratio was 14.21. The lowest was 2.03. And the median was 4.62.
FATE's Cash-to-Debt is ranked worse than 67.86% of 1397
companies
in the Biotechnology industry
Industry Median: 6.72
vs FATE: 2.03
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Fate Therapeutics Cash-to-Debt Related Terms
Fate Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Fate Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Fate Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (FATE) has a Cash-to-Debt of 2.03 as of Jun. 2026. This is 56% below median its historical median of 4.62. Over the past decade, Fate Therapeutics' Cash-to-Debt has ranged from 2.03 to 14.21. According to the industry distribution chart, Fate Therapeutics ranks #948 out of 1397 companies in the Biotechnology industry, placing it in the top 67.9%.
Is Fate Therapeutics' Cash-to-Debt too high?
Fate Therapeutics' current Cash-to-Debt of 2.03 is 56% below median its 10-year median of 4.62. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 14.21. The Biotechnology industry median Cash-to-Debt is 6.72. Fate Therapeutics' value of 2.03 is 69.8% below this industry median. Based on the distribution chart, Fate Therapeutics ranks #948 out of 1397 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Cash-to-Debt compare to RNAC and FULC?
According to the Biotechnology industry distribution chart, Fate Therapeutics ranks #948 out of 1397 companies for Cash-to-Debt. This places Fate Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.72. Fate Therapeutics' value of 2.03 is 69.8% below this benchmark. Historically, Fate Therapeutics' own Cash-to-Debt has ranged from 2.03 to 14.21 over the past decade. While the company's 10-year median is 4.62 vs. the industry median of 6.72, Fate Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fate Therapeutics's current Cash-to-Debt of 2.03 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fate Therapeutics's current Cash-to-Debt is 2.03, which is 56% below median its own 10-year median of 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FATE) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.77, compared to a current price of $2.50 — trading 224.7% above its estimated fair value. The current Cash-to-Debt is 2.03, which is 56% below median its 10-year median of 4.62 and 69.8% below the Biotechnology industry median of 6.72. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Fate Therapeutics (FATE), the current Cash-to-Debt is 2.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fate Therapeutics (FATE) Overvalued in 2026?
Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued.
The current stock price of $2.50 is trading 224.7% above its estimated GF Value™ of $0.77.
GuruFocus considers Fate Therapeutics to be Significantly Overvalued.
Key valuation signals for FATE:
Cash-to-Debt: 2.03 (56% below median its 10-year median of 4.62)
GF Value™: $0.77 vs. price of $2.50 (224.7% above fair value)
Industry Position: 69.8% below the Biotechnology median (#948 of 1397)
No single metric tells the full story. See the FATE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score
Get the complete analysis for FATE
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FATE has been successfully added to your 
